

Francesco Autore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6161088/publications.pdf>

Version: 2024-02-01

45
papers

337
citations

933447

10
h-index

940533

16
g-index

45
all docs

45
docs citations

45
times ranked

649
citing authors

#	ARTICLE	IF	CITATIONS
1	Two types of BCR interactions are positively selected during leukemia development in the E1 $\frac{1}{4}$ -TCL1 transgenic mouse model of CLL. <i>Blood</i> , 2015, 125, 1578-1588.	1.4	52
2	Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. <i>Haematologica</i> , 2018, 103, 931-938.	3.5	31
3	CD200 included in a 4 ϵ marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018, 36, 543-546.	1.7	21
4	Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, 901-908.	2.5	17
5	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Na \tilde{v} e Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	3.7	16
6	HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1340-1342.	1.3	16
7	CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013031.	1.3	14
8	Venetoclax in CLL patients who progress after B ϵ cell Receptor inhibitor treatment: a retrospective multi ϵ centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11.	2.5	14
9	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512.	1.7	13
10	Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. <i>Leukemia and Lymphoma</i> , 2015, 56, 2841-2846.	1.3	11
11	HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2019, 11, 575.	3.7	11
12	Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 993-995.	1.3	10
13	Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2018, 36, 600-603.	1.7	10
14	Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response. <i>Cancers</i> , 2021, 13, 257.	3.7	10
15	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355.	3.5	9
16	New developments in the management of chronic lymphocytic leukemia: role of ofatumumab. <i>OncoTargets and Therapy</i> , 2016, 9, 421.	2.0	8
17	Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2017, 10, 1069-1076.	2.2	8
18	Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poeims syndrome. <i>Hematological Oncology</i> , 2018, 36, 392-398.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience. <i>Frontiers in Oncology</i> , 2021, 11, 614721.	2.8	6
20	“Secondary chronic myeloid leukemia”: comparison between patients previously exposed or not to chemo- and/or radiotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3584-3586.	1.3	5
21	Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience. <i>Hematological Oncology</i> , 2019, 37, 641-643.	1.7	5
22	Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2514-2516.	2.0	5
23	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. <i>Frontiers in Oncology</i> , 2020, 10, 848.	2.8	5
24	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	5.2	5
25	Massive pulmonary embolism at the onset of acute promyelocytic leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016027.	1.3	4
26	Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2021, 39, 423-427.	1.7	4
27	Treatment Options for Elderly/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 5104.	2.4	4
28	Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics. <i>Hematological Oncology</i> , 2022, 40, 469-474.	1.7	4
29	Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid. <i>Leukemia and Lymphoma</i> , 2019, 60, 1328-1330.	1.3	2
30	LDH Levels Predict Progression-Free Survival in Treatment-Naïve Patients with Trisomy 12 Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3211-3211.	1.4	2
31	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. <i>Blood Advances</i> , 2022, 6, 3875-3878.	5.2	2
32	Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience. <i>Hematological Oncology</i> , 2019, 37, 496-497.	1.7	1
33	Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Hematological Oncology</i> , 2021, 39, 267-269.	1.7	1
34	Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression. <i>Blood</i> , 2012, 120, 3888-3888.	1.4	1
35	Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag. <i>Medicina (Lithuania)</i> , 2021, 57, 1326.	2.0	1
36	Successful Second Autologous Stem Cell Transplantation for Late Disease Progression after the First Procedure in POEMS Syndrome. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 2577.	2.5	1

#	ARTICLE	IF	CITATIONS
37	Peyronie's disease in patients with Hodgkin lymphoma. <i>Leukemia Research</i> , 2020, 96, 106427.	0.8	1
38	Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 1100-1104.	1.7	1
39	The concomitance of lymphoma and breast carcinoma in the bone. <i>Annals of Hematology</i> , 2020, 99, 1403-1404.	1.8	0
40	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1780-1780.	1.4	0
41	Chlorambucil PLUS Rituximab As FRONT-LINE THERAPY in Elderly or Unfit Patients Affected by B-CELL Chronic Lymphocytic Leukemia: Results of A Single-Centre Retrospective Analysis. <i>Blood</i> , 2012, 120, 4604-4604.	1.4	0
42	Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study. <i>Blood</i> , 2013, 122, 5309-5309.	1.4	0
43	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. <i>Blood</i> , 2016, 128, 3240-3240.	1.4	0
44	Impact of BCR Stimulation on Mir-181b in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 2026-2026.	1.4	0
45	Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas. <i>Hematological Oncology</i> , 2023, 41, 571-573.	1.7	0